10-Q: Avalon GloboCare Secures $700,000 Investment via Convertible Note and Warrants

Avalon GloboCare Corp. has entered into a securities purchase agreement with Mast Hill Fund, L.P., for a $700,000 convertible note, warrants, and commitment shares.

Summary

• Avalon GloboCare Corp. has secured a $700,000 investment from Mast Hill Fund, L.P., through a securities purchase agreement dated March 7, 2024.
• The agreement includes a promissory note with a principal amount of $700,000, convertible into shares of common stock.
• The purchase price for the note was $665,000, with $35,000 representing an original issue discount.
• In addition to the note, Avalon GloboCare issued warrants to purchase 131,250 shares of common stock (First Warrant) and 121,154 shares of common stock (Second Warrant), as well as 105,000 commitment shares.
• The First Warrant has an exercise price of $2.00 per share, while the Second Warrant has an exercise price of $1.30 per share.
• The Second Warrant is subject to cancellation if the note is fully extinguished by March 7, 2025.
• The note bears interest at 13% per annum and has a maturity date of twelve months from the issue date.
• The agreement also includes a security agreement and a mortgage agreement, granting Mast Hill a security interest in certain assets of Avalon GloboCare.
• The company is obligated to make amortization payments in cash to Mast Hill towards the repayment of the note.

Sentiment

Score: 4

Explanation: The document outlines a necessary financing transaction, but the high interest rate, potential dilution, and default triggers raise concerns. The sentiment is cautiously negative.

Positives

• The company has secured a significant investment of $700,000.
• The agreement includes warrants and commitment shares, which could provide additional capital in the future.
• The security and mortgage agreements provide the investor with added protection.

Negatives

• The note has a high interest rate of 13%.
• The company is obligated to make amortization payments in cash, which could strain cash flow.
• The Second Warrant is subject to cancellation if the note is fully extinguished by March 7, 2025.

Risks

• The company may face challenges in making the required amortization payments.
• The conversion of the note and warrants could dilute existing shareholders.
• The company's market capitalization fell below $5 million, which constitutes an event of default under the 2023 Convertible Notes and the March 2024 Convertible Note.
• The company failed to file its quarterly report in a timely manner, which would have triggered an event of default under the 2023 Convertible Notes and the March 2024 Convertible Note.

Future Outlook

The document outlines the terms of the investment and does not provide specific forward-looking statements about the company's future performance, other than the amortization schedule.

Industry Context

This type of financing is common for small to mid-sized companies seeking capital, particularly those in the biotechnology or healthcare sectors. The use of convertible notes and warrants is a way to attract investors while providing flexibility for the company.

Comparison to Industry Standards

• The terms of this convertible note, including the 13% interest rate, are relatively high compared to those of larger, more established companies.
• The use of warrants as part of the financing package is a common practice in the biotech and healthcare industries, where future growth potential is often a key factor for investors.
• The security and mortgage agreements are typical for secured debt financings, providing the investor with a claim on the company's assets in case of default.
• The conversion price of $1.00 per share is relatively low, which could lead to significant dilution for existing shareholders if the note is converted.

Stakeholder Impact

• Shareholders may experience dilution if the note and warrants are converted.
• Creditors may be impacted by the company's debt obligations.
• Employees may be affected by the company's financial performance.

Next Steps

• The company needs to make amortization payments on the note.
• The company needs to obtain Shareholder Approval to issue all of the Common Stock underlying the Note, Common Stock underlying the Warrants, and Commitment Shares, in excess of 19.99% of the issued and outstanding Common Stock on the Closing Date.
• The company needs to maintain its listing on the Principal Market.
• The company needs to refinance the 2023 Convertible Notes and the March 2024 Convertible Note into one new note.

Key Dates

Keywords

convertible note, warrants, securities purchase agreement, Mast Hill Fund, Avalon GloboCare Corp, investment, common stock, security agreement, mortgage agreement, capital raise